Effect of 10 ng of IL-1β and IL-1Ra in a preliminary recording of the LFPs in the OB. by Adriana Jiménez (3551204)

“…<p>A) A single dose of 10 ng of IL-1β decreased the amplitude of LFPs in the OB immediately after its microinjection, reaching a maximum effect at approximately 10 min and remaining constant for at least 45 min. …”

PP2A inhibition decreases ACS5 accumulation. by Kyle R. Skottke (223882)

Effect of glucagon 200ng/kg on hepatic GSH content. by Rita S. Patarrão (737406)

Effect of glucagon 200ng/kg on hepatic and plasma NO content. by Rita S. Patarrão (737406)

Decreased splicing efficiency in DENV infected cells. by Federico A. De Maio (3091644)

“…<p>(A) Schematic representation of splicing analysis. …”

Mitochondrial respiration of HL-1 cells exposed for 12 or 72h to LG, NG, HG or IHG. by Patrick Mordel (17020879)

Measurement of the MMP in HL-1 cells exposed for 12 or 72h to LG, NG, HG or IHG. by Patrick Mordel (17020879)

Klf5 expression is down-regulated in the ruptured human and experimental AAA. by Dong Ma (584680)

Subjects:

Selective downregulation of SR Ca²⁺ handling proteins and decreased SR Ca²⁺ uptake in TG mice hearts. by Mayilvahanan Shanmugam (691549)

“…For each atrial Ca²⁺ uptake experiment, atria from four mice were pooled. n = 4 for each group. The V_max of Ca²⁺ uptake was obtained at pCa 5.5.…”

RTA 408 Increases Expression of Nrf2 Target Genes and Decreases Expression of Inflammatory Mediators in RAW 264.7 Cells. by Brandon L. Probst (727964)

Down-regulation of pol III activity in hypoxia is not due to a decrease in the abundance of TFIIIB, TFIIIC or pol III subunits by Isabelle Ernens (13462)

Detection of the Challenging mutations at 1% VAF and 50 ng DNA input. by Lizhi Yu (12476136)

Subjects:

Decreased hypotaurine levels within cells lacking the ADO gene in U251 cells. by Hong Tian (169626)

Pretreatment of β-cells with recombinant CXCL12 improves viability and induces a decrease in PARP-1 activity. by Nevena Grdović (394542)

Source data for Fig 1. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 2. by Rahsan Erdem (11726357)

Subjects:

Source data for Fig 3. by Rahsan Erdem (11726357)

Subjects:

Demographics and baseline characteristics of the safety population. by Rahsan Erdem (11726357)

Subjects:

Grading of stool consistency and diarrhea severity. by Rahsan Erdem (11726357)

Subjects:

Secondary efficacy endpoints for the modified intent-to-treat population. by Rahsan Erdem (11726357)

Subjects: